Previous Release | Next Release February 25, 2013 Anacor Pharmaceuticals to Present at the Cowen 33rd Annual Healthcare Conference PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the company's Chief Executive Officer, will provide a company...

Previous Release | Next Release March 21, 2013 Anacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study of AN2728 in Adolescents With Atopic Dermatitis Anacor Will Host a Conference Call Today 8am ET / 5am PT to Discuss Results PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pha...

Previous Release | Next Release April 26, 2013 Anacor Pharmaceuticals Prices $20 Million Public Offering of Common Stock PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has priced an underwritten public offering of 3,129,890 shares of its common stoc...

Previous Release | Next Release May 29, 2013 Anacor Pharmaceuticals Announces Successful Completion of Pre-NDA Communications With the FDA for Tavaborole PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has successfully completed its pre-NDA (New Drug...

Previous Release | Next Release April 8, 2013 Anacor Pharmaceuticals Receives Significant Investment to Support Neglected Disease Research PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that it has signed a research agreement with the Bill & Melinda Gat...